# Relay Therapeutics to Participate in Two Upcoming Investor Conferences in June
Canonical URL: https://biopharmsignal.com/news/RLAY/relay-therapeutics-to-participate-in-two-upcoming-investor-conferences-in-june-9d492b03
Ticker: RLAY
Company: Relay Therapeutics
Source: Relay Therapeutics
Published: 2026-05-27 20:05 EST
## Summary

Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company...

## Article Body
Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, today announced that management will participate in two upcoming fireside chats in June:

2026 Jefferies Global Healthcare Conference on Wednesday, June 3, 2026 at 12:45 p.m. ET

Goldman Sachs 47 th Annual Global Healthcare Conference on Monday, June 8, 2026 at 8:40 a.m. ET

The fireside chats will be webcast live and may be accessed through Relay Therapeutics’ website under Events in the News & Events section through the following link: https://ir.relaytx.com/news-events/events-presentations . An archived replay of the webcast will be available for up to 30 days following the event.

About Relay Therapeutics

Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease. Relay Therapeutics’ Dynamo® platform integrates an array of leading-edge computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The company’s lead clinical asset, zovegalisib, is the first pan-mutant selective PI3Kα inhibitor to enter clinical development and is currently in a Phase 3 clinical trial (ReDiscover-2) in HR+/HER2- metastatic breast cancer. Zovegalisib is also being investigated in a group of genetic disease indications called PI3Kα-driven vascular anomalies. Relay Therapeutics’ pipeline also includes programs for NRAS-driven solid tumors and Fabry disease. For more information, please visit www.relaytx.com or follow us on LinkedIn .

Contact: Mitch Maisel mmaisel@relaytx.com

Media: Dan Budwick 1AB 973-271-6085 dan@1abmedia.com
## Recent Company News
- 2026-05-27 20:05 EST — [Relay Therapeutics to Participate in Two Upcoming Investor Conferences in June](https://biopharmsignal.com/news/RLAY/relay-therapeutics-to-participate-in-two-upcoming-investor-conferences-in-june-9d492b03) — Source: Relay Therapeutics
- 2026-05-21 00:21 EST — [Relay Therapeutics Announces Pricing of Public Offering of Common Stock](https://biopharmsignal.com/news/RLAY/relay-therapeutics-announces-pricing-of-public-offering-of-common-stock-00372d13) — Source: Relay Therapeutics
- 2026-05-19 20:03 EST — [Relay Therapeutics Announces Proposed Public Offering of Common Stock](https://biopharmsignal.com/news/RLAY/relay-therapeutics-announces-proposed-public-offering-of-common-stock-858217e7) — Source: Relay Therapeutics
- 2026-05-19 10:00 EST — [Relay Therapeutics Announces Initial Clinical Data Demonstrating That Zovegalisib Has Potential for Differentiated Safety and Efficacy in Patients with PIK3CA-Driven Vascular Anomalies](https://biopharmsignal.com/news/RLAY/relay-therapeutics-announces-initial-clinical-data-demonstrating-that-zovegalisi-7d0d964f) — Source: Relay Therapeutics
- 2026-05-05 20:05 EST — [Relay Therapeutics Reports First Quarter 2026 Financial Results and Corporate Updates](https://biopharmsignal.com/news/RLAY/relay-therapeutics-reports-first-quarter-2026-financial-results-and-corporate-up-9af87a5e) — Source: Relay Therapeutics
## Related News
- 2026-07-28 20:15 EST — BDX — [BD Board Declares Dividend](https://biopharmsignal.com/news/BDX/bd-board-declares-dividend-ea66eb4a)
- 2026-07-28 13:00 EST — ENLV — [Enlivex Announces $400,000,000 Private Placement](https://biopharmsignal.com/news/ENLV/enlivex-announces-400-000-000-private-placement-20e71a7a)
- 2026-07-28 12:30 EST — XRAY — [Dentsply Sirona Advances Commercial Growth Strategy in Canada Through Expanded Medline Sinclair Relationship](https://biopharmsignal.com/news/XRAY/dentsply-sirona-advances-commercial-growth-strategy-in-canada-through-expanded-m-e2440bb2)
- 2026-07-28 12:30 EST — RLMD — [Relmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia as Chief Business Officer](https://biopharmsignal.com/news/RLMD/relmada-therapeutics-appoints-uro-oncology-leader-bipin-dalmia-as-chief-business-5c4d7b11)
- 2026-07-28 12:05 EST — RIGL — [Rigel Announces Conference Call and Webcast to Report Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/RIGL/rigel-announces-conference-call-and-webcast-to-report-second-quarter-2026-financ-5b987d7a)